Citations

Clear

1434 citation(s) found for "Uk, Nathan".

Cohort study examining associations between ceramide levels and risk of multimorbidity among persons participating in the Mayo Clinic Biobank
Rocca, Walter A. , Sohn, Sunghwan , Weston, Susan A., McGree, Michaela E. , St Sauver, Jennifer L , Rocca, Walter A , Bielinski, Suzette , Sauver, Jennifer L. St. , LeBrasseur, Nathan K. , Olson, Janet E. , Bielinski, Suzette J. , Mielke, Michelle M.

Mayo Clinic

BMJ Open | April 21, 2023 | Volume: 13 | Issue: 4 | Pages: e069375

10.1136/bmjopen-2022-069375 | PMID 37085302 Get It

Objective Ceramides have been associated with several ageing-related conditions but have not been studied as a general biomarker of multimorbidity (MM). Therefore, we determined whether ceramide levels are associated with the rapid development of MM. Design Retrospective cohort study. Setting Mayo Clinic Biobank. Participants 1809 persons in the Mayo Clinic Biobank ≥65 years without MM at the time of enrolment, and with ceramide levels assayed from stored plasma. Primary outcome measure Persons were followed for a median of 5.7 years through their medical records to identify new diagnoses of 20 chronic conditions. The number of new conditions was divided by the person-years of follow-up to calculate the rate of accumulation of new chronic conditions. Results Higher levels of C18:0 and C20:0 were associated with a more rapid rate of accumulation of chronic conditions (C18:0 z score RR: 1.30, 95% CI: 1.10 to 1.53; C20:0 z score RR: 1.26, 95% CI: 1.07 to 1.49). Higher C18:0 and C20:0 levels were also associated with an increased risk of hypertension and coronary artery disease. Conclusions C18:0 and C20:0 were associated with an increased risk of cardiometabolic conditions. When combined with biomarkers specific to other diseases of ageing, these ceramides may be a useful component of a biomarker panel for predicting accelerated ageing.
An overview of the resilience world: Proceedings of the American Geriatrics Society and National Institute on Aging State of Resilience Science Conference
Bandeen‐Roche, Karen , Bergeman, C. S. , Bennett, David A. , Davis, Daniel , Kind, Amy , Whitson, Heather E. , Bennett, David A. , LeBrasseur, Nathan, Abadir, Peter , LeBrasseur, Nathan K. , Stern, Yaakov , Varadhan, Ravi

Mayo Clinic

Journal of the American Geriatrics Society | April 20, 2023 | Volume: 71 | Issue: 8 | Pages: 2381-2392

10.1111/jgs.18388 | PMID 37079440 Get It

Abstract Resilience, which relates to one's ability to respond to stressors, typically declines with age and the development of comorbid conditions in older organisms. Although progress has been made to improve our understanding of resilience in older adults, disciplines have employed different frameworks and definitions to study various aspects of older adults' response to acute or chronic stressors. “Overview of the Resilience World: State of the Science,” a bench‐to‐bedside conference on October 12–13, 2022, was sponsored by the American Geriatrics Society and National Institute on Aging. This conference, summarized in this report, explored commonalities and differences among the frameworks of resilience most commonly used in aging research in the three domains of resilience: physical, cognitive, and psychosocial. These three main domains are intertwined, and stressors in one domain can lead to effects in other domains. The themes of the conference sessions included underlying contributors to resilience, the dynamic nature of resilience throughout the life span, and the role of resilience in health equity. Although participants did not agree on a single definition of “resilience(s),” they identified common core elements of a definition that can be applied to all domains and noted unique features that are domain specific. The presentations and discussions led to recommendations for new longitudinal studies of the impact of exposures to stressors on resilience in older adults, the use of new and existing cohort study data, natural experiments (including the COVID‐19 pandemic), and preclinical models for resilience research, as well as translational research to bring findings on resilience to patient care.
Quantifying lumen diameter in coronary artery stents with high‐resolution photon counting detector CT and convolutional neural network denoising
Koons, Emily K. , Thorne, Jamison E. , Huber, Nathan R. , Chang, Shaojie , Rajendran, Kishore , McCollough, Cynthia H. , Leng, Shuai

Mayo Clinic

Medical Physics | April 18, 2023 | Volume: 50 | Issue: 7 | Pages: 4173-4181

10.1002/mp.16415 | PMID 37069830 Get It

AbstractBackgroundSmall coronary arteries containing stents pose a challenge in CT imaging due to metal‐induced blooming artifact. High spatial resolution imaging capability is as the presence of highly attenuating materials limits noninvasive assessment of luminal patency.PurposeThe purpose of this study was to quantify the effective lumen diameter within coronary stents using a clinical photon‐counting‐detector (PCD) CT in concert with a convolutional neural network (CNN) denoising algorithm, compared to an energy‐integrating‐detector (EID) CT system.MethodsSeven coronary stents of different materials and inner diameters between 3.43 and 4.72 mm were placed in plastic tubes of diameters 3.96–4.87 mm containing 20 mg/mL of iodine solution, mimicking stented contrast‐enhanced coronary arteries. Tubes were placed parallel with or perpendicular to the scanner's z‐axis in an anthropomorphic phantom emulating an average‐sized patient and scanned with a clinical EID‐CT and PCD‐CT. EID scans were performed using our standard coronary computed tomography angiography (cCTA) protocol (120 kV, 180 quality reference mAs). PCD scans were performed using the ultra‐high‐resolution (UHR) mode (120 × 0.2 mm collimation) at 120 kV with tube current adjusted so that CTDIvol was matched to that of EID scans. EID images were reconstructed per our routine clinical protocol (Br40, 0.6 mm thickness), and with the sharpest available kernel (Br69). PCD images were reconstructed at a thickness of 0.6 mm and a dedicated sharp kernel (Br89) which is only possible with the PCD UHR mode. To address increased image noise introduced by the Br89 kernel, an image‐based CNN denoising algorithm was applied to the PCD images of stents scanned parallel to the scanner's z‐axis. Stents were segmented based on full‐width half maximum thresholding and morphological operations, from which effective lumen diameter was calculated and compared to reference sizes measured with a caliper.ResultsSubstantial blooming artifacts were observed on EID Br40 images, resulting in larger stent struts and reduced lumen diameter (effective diameter underestimated by 41% and 47% for parallel and perpendicular orientations, respectively). Blooming artifacts were observed on EID Br69 images with 19% and 31% underestimation of lumen diameter compared to the caliper for parallel and perpendicular scans, respectively. Overall image quality was substantially improved on PCD, with higher spatial resolution and reduced blooming artifacts, resulting in the clearer delineation of stent struts. Effective lumen diameters were underestimated by 9% and 19% relative to the reference for parallel and perpendicular scans, respectively. CNN reduced image noise by about 50% on PCD images without impacting lumen quantification (<0.3% difference).ConclusionThe PCD UHR mode improved in‐stent lumen quantification for all seven stents as compared to EID images due to decreased blooming artifacts. Implementation of CNN denoising algorithms to PCD data substantially improved image quality.
Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
Magro, Fernando , Pai, Rish K. , Kobayashi, Taku , Jairath, Vipul , Rieder, Florian , Redondo, Isabel, Lissoos, Trevor, Shan, Mingyang, Park, Meekyong, Jairath, Vipul , Jairath, Vipul , Jairath, V , Jairath, V , Magro, F , Jairath, Vipul , Kobayashi, Taku , Redondo, Isabel , Morris, Nathan , Shan, Mingyang , Peyrin‐Biroulet, Laurent

Mayo Clinic

Journal of Crohn's and Colitis | April 14, 2023 | Volume: 17 | Issue: 9 | Pages: 1457-1470

10.1093/ecco-jcc/jjad050 | PMID 37057827 Get It

Abstract Background and Aims To evaluate the effect of mirikizumab, a p19-targeted anti-interleukin-23, on histological and/or endoscopic outcomes in moderately-to-severely active ulcerative colitis [UC]. Methods Endoscopic remission [ER], histological improvement [HI], histological remission [HR], histological-endoscopic mucosal improvement [HEMI], and histological-endoscopic mucosal remission [HEMR] were assessed at Week [W]12 [LUCENT-1: N = 1162, induction] and W40 [LUCENT-2: N = 544, maintenance] for patients randomised to mirikizumab or placebo. Analyses were performed to evaluate predictors of: HEMI at W12 with mirikizumab and HEMR at W40 in patients re-randomised to subcutaneous [SC] mirikizumab; associations between W12 histological/endoscopic endpoints and W40 outcomes in mirikizumab responders re-randomised to mirikizumab SC; and associations between W40 endoscopic normalisation [EN] with/without HR. Results Significantly more patients treated with mirikizumab achieved HI, HR, ER, HEMI, and HEMR vs placebo [p &lt;0.001], irrespective of prior biologic/tofacitinib failure [p &lt;0.05]. Lower clinical baseline disease activity, female sex, no baseline immunomodulator use, and no prior biologic/tofacitinib failure were predictors of HEMI at W12 [p &lt;0.05]. Corticosteroid use and longer disease duration were negative predictors of achieving HEMR at W40 [p &lt;0.05]. W12 HI, HR, or ER was associated with W40 HEMI or HEMR [p &lt;0.05]; ER at W12 was associated with clinical remission [CR] [p &lt;0.05] and corticosteroid-free remission [CSFR] at W40 [p = 0.052]. HR and HEMR at W12 were associated with CSFR, CR, and symptomatic remission at W40. Alternate HEMR [EN + HR] at W40 was associated with bowel urgency remission at W40 [p &lt;0.05]. Conclusions Early resolution of endoscopic and histological inflammation with mirikizumab is associated with better UC outcomes. Clinicaltrials.gov: LUCENT-1, NCT03518086; LUCENT-2, NCT03524092.
Pie‐Net: Prior‐information‐enabled deep learning noise reduction for coronary CT angiography acquired with a photon counting detector CT
Chang, Shaojie , Huber, Nathan R. , Marsh, Jeffrey F., Koons, Emily K. , Gong, Hao , Yu, Lifeng , Yu, Lifeng , McCollough, Cynthia H. , Leng, Shuai

Mayo Clinic

Medical Physics | April 12, 2023 | Volume: 50 | Issue: 10 | Pages: 6283-6295

10.1002/mp.16411 | PMID 37042049 Get It

AbstractBackgroundPhoton‐counting‐detector CT (PCD‐CT) enables the production of virtual monoenergetic images (VMIs) at a high spatial resolution (HR) via simultaneous acquisition of multi‐energy data. However, noise levels in these HR VMIs are markedly increased.PurposeTo develop a deep learning technique that utilizes a lower noise VMI as prior information to reduce image noise in HR, PCD‐CT coronary CT angiography (CTA).MethodsCoronary CTA exams of 10 patients were acquired using PCD‐CT (NAEOTOM Alpha, Siemens Healthineers). A prior‐information‐enabled neural network (Pie‐Net) was developed, treating one lower‐noise VMI (e.g., 70 keV) as a prior input and one noisy VMI (e.g., 50 keV or 100 keV) as another. For data preprocessing, noisy VMIs were reconstructed by filtered back‐projection (FBP) and iterative reconstruction (IR), which were then subtracted to generate “noise‐only” images. Spatial decoupling was applied to the noise‐only images to mitigate overfitting and improve randomization. Thicker slice averaging was used for the IR and prior images. The final training inputs for the convolutional neural network (CNN) inside the Pie‐Net consisted of thicker‐slice signal images with the reinsertion of spatially decoupled noise‐only images and the thicker‐slice prior images. The CNN training labels consisted of the corresponding thicker‐slice label images without noise insertion. Pie‐Net's performance was evaluated in terms of image noise, spatial detail preservation, and quantitative accuracy, and compared to a U‐net‐based method that did not include prior information.ResultsPie‐Net provided strong noise reduction, by 95 ± 1% relative to FBP and by 60 ± 8% relative to IR. For HR VMIs at different keV (e.g., 50 keV or 100 keV), Pie‐Net maintained spatial and spectral fidelity. The inclusion of prior information from the PCD‐CT data in the spectral domain was able to improve a robust deep learning‐based denoising performance compared to the U‐net‐based method, which caused some loss of spatial detail and introduced some artifacts.ConclusionThe proposed Pie‐Net achieved substantial noise reduction while preserving HR VMI's spatial and spectral properties.
The First Survival Score for Patients Treated with Whole-Brain Radiotherapy Plus Simultaneous Integrated Boost for Brain Metastases
Rades, Dirk , JOHANNWERNER, LEONIE, Werner, Elisa, Cremers, Florian , Yu, Nathan Y. , Yu, Nathan

Mayo Clinic

Biology | April 12, 2023 | Volume: 12 | Issue: 4 | Pages: 585

10.3390/biology12040585 | PMID 37106785 Get It

A modern approach for brain metastases includes whole-brain radiotherapy plus simultaneous boost (WBRT+SIB). We developed a survival score in 128 patients treated with WBRT+SIB. Three models, each including three prognostic groups, were created. Positive predictive values (PPVs) for death ≤6 and survival ≥6 months were calculated. On multivariate analyses, performance score (KPS) and the number of brain metastases were significantly associated with survival. On univariate analyses, age showed a strong trend, and extra-cerebral cranial metastases a trend. In Model 1 (KPS, number of lesions), compared groups had 6-month survival rates of 15%, 38% and 57%. In Model 2 (KPS, lesions, age), rates were 17%, 33% and 75%, and in Model 3 (KPS, lesions, age, extra-cerebral metastases), 14%, 34% and 78%. PPVs for death ≤6 and survival ≥6 months were 85% and 57% (Model 1), 83% and 75% (Model 2), and 86% and 78% (Model 3). Thus, all models were accurate in predicting death ≤ 6 months; poor-prognosis patients may not benefit from SIB. Models 2 and 3 were superior in predicting survival ≥ 6 months. Given that Model 3 requires more data (including extensive staging), Model 2 is considered favorable for many patients. If extra-cerebral metastases are already known or extensive staging has been performed, Model 3 can also be used.
Clinical metrics and tools for provider assessment and tracking of trigonocephaly
Chern, Joshua J. , Ahn, Edward S. , Chamis, Megan, Paro, Mitch R., Lambert, William A. , Stoltz, Petronella, Hersh, David S. , Martin, Jonathan E. , Leclair, Nathan K. , Bookland, Markus J.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | April 7, 2023 | Volume: 32 | Issue: 1 | Pages: 82-90

10.3171/2023.2.peds22511 | PMID 37029682 Get It

OBJECTIVE Quantitative measurements of trigonocephaly can be used to characterize and track this phenotype, which is associated with metopic craniosynostosis. Traditionally, trigonocephaly metrics were extracted from CT scans; however, this method exposes patients to ionizing radiation. Three-dimensional optical scans are another option but are not routinely available in most outpatient settings. Recently, the authors developed semiautomated artificial intelligence algorithms that extract craniometric data from orthogonal 2D photographs. Although 2D photographs are safe, inexpensive, and straightforward to obtain, the accuracy of photograph-based craniometrics in comparison to CT and 3D optical scan correlates has not been established. In this study the authors compared the classification power of 2D photograph–based metrics of trigonocephaly with four CT-based metrics and one 3D optical scan–based metric in a heterogeneous series of patients who presented to an outpatient craniofacial clinic. METHODS In this study the authors performed retrospective craniometric analyses of patient 2D photographs, 3D optical scans, and CT scans. Imaging-derived craniometrics include the 2D photograph–based anterior arc angle (AAA2D-photo), anterior-posterior ratio (APR2D-photo), and anterior-middle ratio (AMR2D-photo); the CT-based anterior arc angle (AAACT), metopic index (MICT), endocranial-bifrontal angle (eBFACT), and interfrontal angle (IFACT); and the 3D optical scan–based anterior arc angle (AAA3D-optical). Receiver operating characteristics (ROCs) were used to identify craniometrics strongly descriptive of trigonocephaly. Interrater comparisons were made between paired trigonocephaly measurements obtained from photographs and either CT scans or 3D optical scans. RESULTS There were 13 photograph-based and CT-based pairs and 22 paired measurements from 2D photographs and 3D optical scans. AAA displayed the strongest classification capacity across all three imaging modalities. Significant agreement was observed between AAACT and AAA2D-photo (intraclass correlation coefficient [ICC] = 0.68 [95% CI 0.24–0.89], p = 0.0035), and AAA3D-optical and AAA2D-photo (ICC = 0.70 [95% CI 0.41–0.87], p < 0.0001). There was no significant correlation between APR2D-photo or AMR2D-photo and conventional CT-based metrics describing longitudinal width ratios (MICT). CONCLUSIONS Photograph-based craniometrics are powerful tools that can be used to quantify the severity of trigonocephaly and exhibit high concordance with standard measurements derived from CT scans and 3D optical scans. The authors developed and freely share a research-use application to calculate trigonocephaly metrics from 2D photographs. Given the availability of digital photography, lack of ionizing radiation, and low cost of photograph-based craniometric derivation, this technique may be useful to supplement routine ambulatory care and objectively track outcomes following treatment.
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
Major, Ajay , Yu, Jovian , Shukla, Navika , Karrison, Theodore , Treitman, Rachel, Haverkos, Bradley M. , Godfrey, James , Babcook, Melissa A., Voorhees, Timothy , Carlson, Sophie G. , Gaut, Daria , Oliai, Caspian , Winter, Allison , Hill, Brian T. , Bansal, Radhika , Nizamuddin, Imran , Fitzgerald, Lindsey , Stephens, Deborah M. , Hu, Marie , Bachanová, Veronika , Slade, Michael , Singh, Nathan , Bishop, Michael R. , Riedell, Peter A. , Haverkos, Bradley M , Voorhees, Timothy J , Romancik, Jason T , Bansal, Radhika , Villasboas, Jose Caetano , Karmali, Reem , Stephens, Deborah M , Pophali, Priyanka , Trabolsi, Asaad , Schatz, Jonathan H , Hu, Marie , Slade, Michael J , Singh, Nathan , Ahmed, Nausheen , McGuirk, Joseph , Riedell, Peter A , Bachanova, Veronika , Major, Ajay , Che, Yan, Kamdar, Manali , Oliai, Caspian H , Romancik, Jason T. , Villasboas, José C. , Karmali, Reem , Pophali, Priyanka A. , Ahmed, Nausheen , McGuirk, Joseph P. , Bishop, Michael Russell , Kline, Justin Paul

Mayo Clinic

Blood Advances | April 7, 2023 | Volume: 7 | Issue: 16 | Pages: 4528-4538

10.1182/bloodadvances.2023010016 | PMID 37026796 Get It

AbstractCheckpoint inhibitor (CPI) therapy with anti–PD-1 antibodies has been associated with mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas after CAR-T failure. To define CPI therapy efficacy more definitively in this population, we retrospectively evaluated clinical outcomes in a large cohort of 96 patients with aggressive B-cell lymphomas receiving CPI therapy after CAR-T failure across 15 US academic centers. Most patients (53%) had diffuse large B-cell lymphoma, were treated with axicabtagene ciloleucel (53%), relapsed early (≤180 days) after CAR-T (83%), and received pembrolizumab (49%) or nivolumab (43%). CPI therapy was associated with an overall response rate of 19% and a complete response rate of 10%. Median duration of response was 221 days. Median progression-free survival (PFS) and overall survival (OS) were 54 and 159 days, respectively. Outcomes to CPI therapy were significantly improved in patients with primary mediastinal B-cell lymphoma. PFS (128 vs 51 days) and OS (387 vs 131 days) were significantly longer in patients with late (&gt;180 days) vs early (≤180 days) relapse after CAR-T. Grade ≥3 adverse events occurred in 19% of patients treated with CPI. Most patients (83%) died, commonly because of progressive disease. Only 5% had durable responses to CPI therapy. In the largest cohort of patients with aggressive B-cell lymphoma treated with CPI therapy after CAR-T relapse, our results reveal poor outcomes, particularly among those relapsing early after CAR-T. In conclusion, CPI therapy is not an effective salvage strategy for most patients after CAR-T, where alternative approaches are needed to improve post–CAR-T outcomes.
Impact of bortezomib‐based versus lenalidomide maintenance therapy on outcomes of patients with high‐risk multiple myeloma
Bumma, Naresh , Dhakal, Binod , Fraser, Raphael , Estrada‐Merly, Noel, Freytes, César O. , Hildebrandt, Gerhard , Holmberg, Leona , Krem, Maxwell M. , Lekakis, Lazaros J. , Mian, Hira , Nathan, Sunita , Solh, Melhem , Strouse, Christopher , Vesole, David H. , Kumar, Shaji , Qazilbash, Muzaffar H. , Shah, Nina , Sidana, Surbhi , Holmberg, Leona , Mian, Hira , Nishihori, Taiga , Parrondo, Ricardo D , Kumar, Shaji K , Qazilbash, Muzaffar H , Shah, Nina , D'Souza, Anita , Sidana, Surbhi , Strouse, Christopher S , Dhakal, Binod , Anderson, Kenneth C. , Lee, Cindy , Lazarus, Hillard M. , Murthy, Hemant S. , Nishihori, Taiga , Patel, Sagar S. , D’Souza, Anita

Mayo Clinic

Cancer | April 6, 2023 | Volume: 129 | Issue: 14 | Pages: 2179-2191

10.1002/cncr.34778 | PMID 37021929 Get It

AbstractBackgroundLenalidomide maintenance after autologous stem cell transplant (ASCT) in multiple myeloma (MM) results in superior progression‐free survival and overall survival. However, patients with high‐risk multiple myeloma (HRMM) do not derive the same survival benefit from lenalidomide maintenance compared with standard‐risk patients. The authors sought to determine the outcomes of bortezomib‐based maintenance compared with lenalidomide maintenance in patients with HRMM undergoing ASCT.MethodsIn total, the authors identified 503 patients with HRMM who were undergoing ASCT within 12 months of diagnosis from January 2013 to December 2018 after receiving triplet novel‐agent induction in the Center for International Blood and Marrow Transplant Research database. HRMM was defined as deletion 17p, t(14;16), t(4;14), t(14;20), or chromosome 1q gain.ResultsThree hundred fifty‐seven patients (67%) received lenalidomide alone, and 146 (33%) received bortezomib‐based maintenance (with bortezomib alone in 58%). Patients in the bortezomib‐based maintenance group were more likely to harbor two or more high‐risk abnormalities and International Staging System stage III disease (30% vs. 22%; p = .01) compared with the lenalidomide group (24% vs. 15%; p < .01). Patients who were receiving lenalidomide maintenance had superior progression‐free survival at 2 years compared with those who were receiving either bortezomib monotherapy or combination therapy (75% vs. 63%; p = .009). Overall survival at 2 years was also superior in the lenalidomide group (93% vs. 84%; p = .001).ConclusionsNo superior outcomes were observed in patients with HRMM who received bortezomib monotherapy or (to a lesser extent) in those who received bortezomib in combination as maintenance compared with lenalidomide alone. Until prospective data from randomized clinical trials are available, post‐transplant therapy should be tailored to each patient with consideration for treating patients in clinical trials that target novel therapeutic strategies for HRMM, and lenalidomide should remain a cornerstone of treatment.
Abstract 990: Immune-suppressive tumor microenvironment leads to poor survival following curative intent surgical resection in soft-tissue sarcomas
Asmann, Yan W. , Almerey, Tariq , Attia, Steven , Seligson, Nathan D. , Bagaria, Sanjay P.

Mayo Clinic

Cancer Research | April 5, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 990-990

10.1158/1538-7445.am2023-990 Get It

Abstract Surgical resection of early stage soft-tissue sarcomas (STS) is a potentially curative treatment; however, many STS tumors will recur. Predicting recurrence and survival outcomes for patients with early stage STS remains a challenge. In this study, we identify prognostic biomarkers from clinical and transcriptomic data form a large set of early stage STS. Primary tumor samples from 69 subjects with STS were sequenced using the Tempus xT targeted DNA and whole transcriptome next-generation sequencing platforms. The most common histologies included were liposarcoma (n=22), gastrointestinal stromal tumor (n=19), and leiomyosarcoma (n=12). As expected, high-grade tumors were associated with decreased DFS and OS times while tumor histology was only correlated with OS. Single sample gene set enrichment analysis (ssGSEA) values for seven Hallmark genesets were correlated with both DFS and OS; including pro-tumor survival pathways (p53, Apoptosis, TNF-α via NF-κB), tumor proliferation pathways (MTORC1, MYC Targets, Mitotic Spindle), and UV Response signaling. These pathways are associated with tumor proliferation as well as an immunosuppressive tumor microenvironment (TME). To assess the TME of these tumors we estimated immune cell infiltration using CIBERSORTx. Of the 22 cell types accounted for by CIBERSORTx, only elevated infiltration of M2 Macrophages were associated with poor DFS and OS. To further determine TME activation we assessed the expression of 74 known immune response associated genes. Only PDCD1 (PD-1) was associated with reduced DFS and OS times. Clustering on the nine variables identified here to correlate with both DFS and OS revealed two distinct clusters demonstrating similar histologies. While histologies were similar across clusters, cluster 2 exclusively included high-grade tumors while cluster 1 was made up of 57.4% high-grade tumors. Sub-classifying cluster 1 into low and high-grade subgroups demonstrated a stepped biomarker expression pattern associated with both tumor grade and cluster membership. Using established TME genesets, high-grade tumors demonstrated higher tumor proliferative scores than low-grade tumors, while cluster 2 tumors demonstrated increased tumor associated macrophage signaling. In a multivariable model, cluster membership outperformed tumor grade and histology as the only significant predictor of DFS or OS. Taken together, while tumor grade is a strong predictor of clinical outcomes following surgical resection in STS, immunosuppressive signaling patters may help to identify patients at the highest risk. Citation Format: Nathan David Seligson, Yan W. Asmann, Tariq Almerey, Steven Attia, Sanjay P. Bagaria. Immune-suppressive tumor microenvironment leads to poor survival following curative intent surgical resection in soft-tissue sarcomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 990.